Form 4: Mirum CFO's RSU Vesting and Tax-Related Stock Sale

Mirum Pharmaceuticals' CFO, Eric Bjerkholt, reported the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations.

Summary

• Eric Bjerkholt, Chief Financial Officer of Mirum Pharmaceuticals, Inc. (MIRM), reported transactions involving the company's common stock.
• On January 23, 2026, 2,667 restricted stock units (RSUs) vested, converting into 2,667 shares of common stock.
• Following the vesting, on January 26, 2026, Bjerkholt sold 1,053 shares of common stock at a price of $96.192 per share.
• This sale was explicitly stated to cover tax withholding obligations associated with the RSU vesting.
• After these transactions, Bjerkholt directly beneficially owns 43,741 shares of common stock and 2,666 restricted stock units.

Sentiment

Score: 6

Explanation: Neutral to slightly positive. The vesting of RSUs is a positive sign of executive compensation and retention, while the subsequent sale is a routine tax-related event, not indicative of a lack of confidence.

Positives

• The vesting of 2,667 restricted stock units indicates continued compensation and retention of a key executive.

Negatives

• A net reduction of 1,053 shares in direct beneficial ownership due to the tax-related sale.

Future Outlook

No forward-looking statements or guidance were provided in this filing.

Industry Context

This is a routine insider transaction (vesting and tax-related sale) for a pharmaceutical company executive and does not provide broader industry context.

Stakeholder Impact

• Shareholders: Minor dilution from RSU vesting, but the tax-related sale is a routine event. The overall change in beneficial ownership is small relative to total shares outstanding.
• Employees: The RSU vesting demonstrates the company's compensation structure for executives.

Next Steps

• The remaining 2,666 restricted stock units will continue to vest annually on January 23, 2024 anniversaries until fully vested on the three-year anniversary of the Vesting Commencement Date.

Key Dates

Recommendation

The filing details a routine insider transaction involving the vesting of restricted stock units and a subsequent sale of shares to cover tax obligations. This type of transaction is common for executive compensation and does not typically signal a change in the company's fundamentals or management's outlook. Therefore, it provides no new information to warrant a change from a 'hold' position.

Keywords

Mirum Pharmaceuticals, MIRM, Form 4, Insider Transaction, Eric Bjerkholt, CFO, Restricted Stock Units, RSU Vesting, Stock Sale, Tax Withholding, Beneficial Ownership